文献速递免疫规划妇幼与学校卫生

包膜病毒样颗粒铝佐剂巨细胞病毒疫苗安全且具免疫原性:加拿大免疫研究网络(CIRN)首次人体研究

An enveloped virus-like particle alum-adjuvanted cytomegalovirus vaccine is safe and immunogenic: A first-in-humans Canadian Immunization Research Network (CIRN) study.
PubMed 文献 · Vaccine · 2023-12-22

该首次人体、随机、安慰剂对照、观察者盲法、剂量递增研究在125名18至40岁CMV血清阴性健康成人中评估包膜病毒样颗粒(eVLP)CMV疫苗的安全性及免疫原性,受试者随机接受0.5 µg、1 µg或2 µg gB加铝佐剂、1 µg gB不加铝佐剂或安慰剂,于第0、56、168天肌内注射。结果显示疫苗具免疫原性,铝佐剂、更高抗原含量及三剂程序增强免疫应答,未观察到安全性信号。

要点

  • 最常见征集性局部和全身不良事件分别为疼痛和头痛。
  • 第2、3剂后gB结合、亲和力及中和抗体滴度呈剂量依赖性升高,铝佐剂2.0 µg组第3剂后滴度最高。
  • 铝佐剂2.0 µg组100%受试者对成纤维细胞CMV感染产生中和活性,31%对上皮细胞感染产生中和活性。

核心结论

  • eVLP CMV疫苗在健康CMV血清阴性成人中具免疫原性,未观察到安全性信号。
  • 铝佐剂、更高抗原含量及三剂程序增强免疫原性。
  • 该1期试验支持该eVLP CMV疫苗候选物的进一步开发。

研究设计与样本

  • 首次人体、剂量递增、随机、安慰剂对照、观察者盲法研究。
  • 在3个加拿大研究中心纳入125名18至40岁健康CMV血清阴性成人。
  • 随机接受0.5 µg、1 µg或2 µg gB加铝佐剂、1 µg gB不加铝佐剂或安慰剂,于第0、56、168天肌内注射。

主要发现

  • 最常见征集性局部和全身不良事件分别为疼痛和头痛。
  • 第2、3剂后gB结合、亲和力及中和抗体滴度呈剂量依赖性升高,铝佐剂2.0 µg组第3剂后滴度最高。
  • 铝佐剂2.0 µg组中24%对广谱中和AD-2表位产生应答。
  • 铝佐剂2.0 µg组100%受试者对成纤维细胞CMV感染产生中和活性,31%对上皮细胞感染产生中和活性。
  • 上皮细胞中和抗体滴度与更高的CMV gB结合抗体几何均值滴度正相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Cytomegalovirus (CMV) is the most common cause of congenital infection and affected children often have permanent neurodevelopmental sequelae, including hearing loss and intellectual disability. Vaccines to prevent transmission of CMV during pregnancy are a public health priority. This first-in-humans dose-ranging, randomized, placebo-controlled, observer-blinded study evaluated the safety and immunogenicity of an enveloped virus-like particle (eVLP) vaccine expressing a modified form of the CMV glycoprotein B (gB). METHODS: Healthy CMV-seronegative 18 to 40-year-olds at 3 Canadian study sites were randomized to one of 4 dose formulations (0.5 µg, 1 µg, or 2 µg gB content with alum) or 1 µg gB without alum, or placebo, given intramuscularly on days 0, 56 and 168. Outcome measures were solicited and unsolicited adverse events (AE), severe AE, gB and AD-2 epitope binding antibody titers and avidity, and neutralizing antibody (nAb) titers to CMV measured in fibroblast and epithelial cell infection assays. RESULTS: Among 125 participants, the most common solicited local and general AEs were pain and headache, respectively. A dose-dependent increase in gB binding, avidity and nAb titers was observed after doses 2 and 3, with the highest titers in the alum-adjuvanted 2.0 µg dose recipients after the third dose; in the latter 24 % had responses to the broadly neutralizing AD-2 epitope. Neutralizing activity to CMV infection of fibroblasts was seen in 100 % of 2.0 µg alum-adjuvanted dose recipients, and to epithelial cell infection in 31 %. Epithelial cell nAb titers were positively correlated with higher geometric mean CMV gB binding titers. CONCLUSIONS: An eVLP CMV vaccine was immunogenic in healthy CMV-seronegative adults and no safety signals were seen. Alum adjuvantation increased immunogenicity as did higher antigen content and a three dose schedule. This phase 1 trial supports further development of this eVLP CMV vaccine candidate.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Langley JM, Gantt S, Halperin SA, et al. An enveloped virus-like particle alum-adjuvanted cytomegalovirus vaccine is safe and immunogenic: A first-in-humans Canadian Immunization Research Network (CIRN) study. Vaccine. 2023. PMID: 38142214. doi:10.1016/j.vaccine.2023.12.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。